Skip to main content
Rize Recovery logo
Rize Recovery
Drug Class · Substance Pillar

Opioids

Natural and synthetic substances acting on opioid receptors, ranging from prescription analgesics to fentanyl analogs.

115 stories·8 lenses·Read the definitive guide →

Latest reporting

Through eight lenses

01

Science

Opioids bind to μ, δ, and κ receptors in the central and peripheral nervous system. Agonists (morphine, heroin, fentanyl) produce analgesia, euphoria, and respiratory depression; partial agonists (buprenorphine) and antagonists (naloxone, naltrexone) occupy receptors differently. Fentanyl's potency (~50–100× morphine) reflects receptor affinity, not a different mechanism — which is why overdose reversal still works, just often requiring higher or repeated naloxone doses.

02

Biology

Acute effects: respiratory depression (the killer), miosis, GI slowdown, analgesia. Chronic use downregulates endogenous opioid production, which is the neurobiology behind withdrawal — real, measurable, not "in someone's head." Long-term health impacts include endocrine suppression, constipation, cardiovascular stress, and (with injection) endocarditis and soft-tissue infections. Fentanyl's pharmacokinetics (rapid onset, short half-life in plasma but redistribution into tissue) explain its overdose profile.

03

Psychology

Opioid use disorder has the highest bio-genetic contribution of any SUD in twin studies (~50–60% heritability). The "warm blanket" subjective experience — which people in active use describe consistently — reflects μ-receptor activation in regions governing social pain. That's why opioids map so cleanly onto trauma, loneliness, and chronic pain.

04

Policy

Schedule II (except buprenorphine at III, heroin at I). DEA quota system governs legitimate supply. The 2023 X-Waiver elimination removed the barrier to buprenorphine prescribing — any provider with a Schedule III DEA number can now prescribe. [Telehealth prescribing is extended through 2026](/newsroom/dea-extends-telemedicine-buprenorphine-2026) with permanent 6-month flexibility for buprenorphine.

05

Trends

CDC provisional data shows ~72,000 overdose deaths in the 12 months ending October 2025, a 17% decline from the 2023 peak of ~107,000. Synthetic opioids (fentanyl + analogs) remain in 69–75% of these deaths. Emerging: nitazenes (more potent than fentanyl, naloxone-reversible but may require higher doses) and xylazine (not an opioid, but in the supply — see [SP-15](/newsroom/xylazine-what-it-is-why-it-matters)).

06

Social & Cultural

From Bayer's 1898 heroin marketing through the Harrison Act, to Purdue's OxyContin launch and the three waves of the modern crisis (prescription → heroin → fentanyl), opioid policy has always been racialized and regional. The Sackler settlements and the broader $50B national opioid settlement represent the largest public-health financial remediation in U.S. history.

07

Treatment

[MAT](/newsroom/mat-explained-2026) is the evidence-based standard: buprenorphine, methadone, and extended-release naltrexone all reduce mortality by ~50% vs. non-medication treatment in meta-analyses. Counseling helps but is not required to start MAT. Residential programs, IOP, peer recovery coaching, and 12-step all have roles, but without MAT the evidence for OUD treatment alone is weak.

08

Harm Reduction

Naloxone saves lives and is now available OTC (Narcan) in most states. Fentanyl test strips, safer-use education, Good Samaritan protections, syringe service programs, and (in some jurisdictions) overdose prevention centers. Harm reduction is not antithetical to recovery — SAMHSA's 2022 harm reduction pillar makes this explicit.

Substances in this class